S-Adenosyl-L-Methionine Augmentation in Patients With Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study.

S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study.

ScientificWorldJournal. 2013; 2013: 204649
De Berardis D, Marini S, Serroni N, Rapini G, Iasevoli F, Valchera A, Signorelli M, Aguglia E, Perna G, Salone A, Di Iorio G, Martinotti G, Di Giannantonio M

We investigated the efficacy of S-Adenosyl-L-Methionine (SAMe) augmentation in patients with treatment-resistant depressive disorder (TRD). Thirty-three outpatients with major depressive episode who failed to respond to at least 8 weeks of treatment with two adequate and stable doses of antidepressants were treated openly with fixed dose of SAMe (800?mg) for 8 weeks, added to existing medication. The primary outcome measure was the change from baseline in total score on Hamilton Rating Scale for Depression (HAM-D). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on HAM-D total score and a CGI-I score of 1 or 2 at endpoint were considered responders; remission was defined as a HAM-D score ?7. Secondary outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Sheehan Disability Scale (SDS). At 8 weeks, a significant decrease in HAM-D score was observed with response achieved by 60% of the patients and remission by 36%. Also a statistically significant reduction in SHAPS and SDS was observed. Our findings indicate that SAMe augmentation may be effective and well tolerated in stage II TRD. However, limitations of the present study must be considered and further placebo-controlled trials are needed. HubMed – depression


Erratum: Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum].

Neuropsychiatr Dis Treat. 2013; 9: 813

[This corrects the article on p. 813 in vol. 9.]. HubMed – depression


Balance and gait in older electroconvulsive therapy recipients: a pilot study.

Neuropsychiatr Dis Treat. 2013; 9: 805-12
Plakiotis C, Barson F, Vengadasalam B, Haines TP, O’Connor DW

Electroconvulsive therapy (ECT) is commonly used to treat depression in older adults. Despite its efficacy in this regard, an associated increase in the risk of falls in this population is a downside of treatment. ECT research has focused on the incidence of falls, but its effect on balance and gait – intrinsic factors in instability and falls – has not been studied. Our aim was to examine changes in balance and gait among older adults before and after a single ECT session and explore the effect of patient-related and treatment factors on any changes found.Participants were 21 older adults requiring ECT for depression in public psychiatric services. Patients with clinically overt mobility problems (impairing test participation or increasing the risk of falls) were excluded. Balance and gait testing 1 hour pre-ECT and 1, 2 and 3 hours post-ECT included: (1) steady standing test; (2) perturbation of standing balance by self-initiated movements; (3) perturbation of standing balance by an external perturbation; and (4) timed up and go test.No deterioration in test performance was found, using one-way repeated measures analysis of variance.Balance and gait did not deteriorate immediately after ECT. Exclusion of participants with clinically overt mobility problems and falls being better attributable to factors unrelated to balance and gait (such as post-ECT confusion) may account for our findings. This research does not repudiate the occurrence of ECT-related falls but calls into question the utility of introducing routine balance and gait assessment among older ECT recipients without pre-existing mobility problems as a means of preventing them. HubMed – depression



Palo Alto Psychotherapists – Depression Treatment – http://EntelechyWellness.com – Depression treatment. Entelechy Wellness offers therapy and counseling to help people recover from depression in San Francisco…